Academic/Biomedical Research
News & Jobs

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

News | News By Subject | News by Disease | News By Date | Search News

Get Our Industry eNewsletter FREE

email:

Targeted Molecular Diagnostics, LLC (TMD) Introduces KRAS Mutation Assay to Identify KRAS Mutations in Patients With Metastatic Colorectal Cancer

5/29/2008 10:27:39 AM

WESTMONT, IL--(Marketwire - May 28, 2008) - Targeted Molecular Diagnostics (TMD) announces the commercial availability of a new clinical laboratory test to identify colorectal cancer (CRC) patients who may be resistant to EGFR targeted monoclonal antibody therapies. Recently, colorectal cancer patients who harbor KRAS mutations were shown to have no response to antibody-based EGFR therapies such as cetuximab and panitumumab. Mutated KRAS genes have been detected in about 40% of metastatic colorectal cancers. In one study, TMD identified mutations in 43% of CRC patients using the Real-Time PCR platform. TMD's KRAS Mutation Assay may help identify patients who harbor specific KRAS mutations and therefore may not respond to EGFR inhibitors.

Read at BioSpace.com

• BioSpace.com

• Targeted Molecular Diagnostics, LLC (TMD)

• Diagnostics

• Medical Dev. & Diag. - Product News

• Colorectal cancer